Search Medical Condition
Please enter condition
Please choose location

Juan Diaz, Panama Clinical Trials

A listing of Juan Diaz, Panama clinical trials actively recruiting patients volunteers.

RESULTS

Found (31) clinical trials

This Study Will Evaluate the Persistence of Hepatitis A Antibodies 8 Years and 10 Years Later in Children Who Had Received Havrix at Selected Health Centres of Panama in 2007-2008

The study comprises of two independent cross-sectional surveys (Year 8 and Year 10). The first cross-sectional serosurvey will evaluate the long term persistence of immunity approximately 8 years post vaccine administration and the second cross-sectional study will evaluate long term persistence, approximately 10 years post vaccine administration.

Phase N/A

0.0 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with proliferative LN.

Phase

5.45 miles

Learn More »

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

This is a Phase III/IV, single-arm, multicenter study of the long-term safety and efficacy of atezolizumab treatment in participants with Stage IIIb or Stage IV NSCLC who have progressed after standard systemic chemotherapy (including if given in combination with anti-programmed cell death protein 1 [anti-PD-1] therapy or after anti-PD-1 as ...

Phase

5.45 miles

Learn More »

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other agents in a Genentech/Roche-sponsored parent study who are active and deriving benefit at the closure of parent study are eligible for continued treatment in this study.

Phase

5.45 miles

Learn More »

A Study to Evaluate the Antiviral Activity Clinical Outcomes Safety Tolerability and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

The purpose of this study is to determine in hospitalized infants and children who are infected with respiratory syncytial virus (RSV) the dose-response relationship of multiple regimens of lumicitabine on antiviral activity based on nasal RSV shedding using quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR).

Phase

5.45 miles

Learn More »

Distal Tibia Sarcoma Treatment Using Allograft Arthrodesis of the Ankle

It is well known that before the 1980`s the usual treatment for the sarcomas of the distal tibia was amputation (1). Currently, however, after the improvement of the chemotherapy treatments, potential reconstructions of the area in well studied patients are possible, and for that we have a wide range: auto ...

Phase N/A

5.45 miles

Learn More »

A Study of ALS-008176 in Infants Hospitalized With RSV

This study will assess the safety, tolerability, pharmacokinetics (PK) and anti-viral effect of single and multiple doses of ALS-008176 in infants hospitalized with respiratory syncytial virus (RSV)

Phase

6.94 miles

Learn More »

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

The purpose of this study is to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients receiving open-label investigational drug.

Phase

6.94 miles

Learn More »

Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen

Cohorts 2, 3, and 4 will be on a boosted protease inhibitor (PI) or any other 3rd ARV agent and will switch their current 2-NRTI-containing regimen to open-label F/TAF while continuing their boosted PI or 3rd agent through 48 weeks. A minimum of 10 participants each in Groups 1 and ...

Phase

6.94 miles

Learn More »

Study to Evaluate the Efficacy and Safety of REGN2222 for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

This study occurs in two parts: Part A and Part B. The status of Part A is 'Complete'. The status of Part B is 'Recruiting.' Part A of the study is an open-label, PK evaluation of intramuscular (IM) administered REGN2222 in preterm infants for whom palivizumab is not recommended to ...

Phase

6.94 miles

Learn More »